Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: Results from the EXCLAIM study
Alexander G.G. Turpie
, Russell D. Hull
, Sebastian M. Schellong
, Victor F. Tapson
, Manuel Monreal
, Meyer Michel Samama
, Min Chen
,
Roger D. Yusen
Institute of Clinical and Translational Sciences (ICTS)
Division of Pulmonary & Critical Care Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
26
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: Results from the EXCLAIM study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Extended Duration
100%
Enoxaparin
100%
Venous Thromboembolism Risk
100%
Ischemic Stroke Patients
100%
Placebo
57%
Major Bleeding
42%
Venous Thromboembolism
42%
Ischemic Stroke
28%
Acutely Ill Patients
28%
Absolute Risk Difference
28%
Extended-duration Thromboprophylaxis
28%
Placebo Groups
14%
Bleeding Rate
14%
Unique Identifier
14%
Clinical Trial Registry
14%
Stroke Patients
14%
Fatal Pulmonary Embolism
14%
Reduced Mobility
14%
Acute Stroke
14%
Venous Thromboembolism Prophylaxis
14%
Optimal Duration
14%
Prolonged Immobilization
14%
Extended Prophylaxis
14%
Asymptomatic Deep Vein Thrombosis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Ischemia
100%
Venous Thromboembolism
100%
Enoxaparin
100%
Placebo
71%
Bleeding
42%
Clinical Trial
14%
Deep Vein Thrombosis
14%
Lung Embolism
14%
Cerebrovascular Accident
14%